Back to Search
Start Over
Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist.
- Source :
-
Journal of Asian natural products research [J Asian Nat Prod Res] 2023 May; Vol. 25 (5), pp. 484-496. Date of Electronic Publication: 2022 Jul 22. - Publication Year :
- 2023
-
Abstract
- Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibited rosiglitazone-induced adipocyte differentiation of 3T3-L1 cells, and lipid accumulation in palmitic acid (PA)-induced HepG2 cells with down-regulated mRNA expression of lipogenesis-related genes. In addition, it was predicted to bind to the ligand binding domain (LBD) of PPARγ and inhibit its transactivity. Collectively, our study suggested that ASI improves lipid metabolism in obese mice probably through suppressing PPARγ activity.
Details
- Language :
- English
- ISSN :
- 1477-2213
- Volume :
- 25
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Journal of Asian natural products research
- Publication Type :
- Academic Journal
- Accession number :
- 35866240
- Full Text :
- https://doi.org/10.1080/10286020.2022.2098726